Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,940 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 2,940 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $102,047.40. Following the completion of the transaction, the insider owned 80,277 shares in the company, valued at $2,786,414.67. The trade was a 3.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Agios Pharmaceuticals Price Performance

AGIO stock traded down $0.40 during midday trading on Monday, reaching $34.80. The company had a trading volume of 1,068,723 shares, compared to its average volume of 933,677. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The stock has a 50 day moving average price of $28.88 and a 200-day moving average price of $32.14. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -4.89 and a beta of 0.79.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP grew its position in shares of Agios Pharmaceuticals by 31.4% during the 2nd quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock valued at $22,772,000 after purchasing an additional 163,796 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Agios Pharmaceuticals in the third quarter worth $2,696,000. HighVista Strategies LLC boosted its stake in Agios Pharmaceuticals by 178.5% during the third quarter. HighVista Strategies LLC now owns 195,298 shares of the biopharmaceutical company’s stock valued at $7,839,000 after buying an additional 125,171 shares during the period. Frazier Life Sciences Management L.P. boosted its position in shares of Agios Pharmaceuticals by 19.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock valued at $42,565,000 after acquiring an additional 209,900 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its stake in Agios Pharmaceuticals by 71.1% during the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock worth $14,868,000 after purchasing an additional 185,798 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AGIO. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. JPMorgan Chase & Co. upped their target price on Agios Pharmaceuticals from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Monday. Bank of America raised their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Finally, Citigroup lifted their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $42.67.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.